Further clinical studies to evaluate combinations of hormone therapy with PI3K, AKT, mTOR, or CDK 4/6 inhibitors, together with clinical trials in other breast subtypes, are still ongoing and will lead to improved therapies to treat breast cancer patients. The gene discussed is AKT1; the disease is breast carcinoma.